Apheresis Market

Terumo BCT, Inc. (Japan) and Fresenius SE & Co. KGaA (Germany) are leading Players in the Apheresis Market

The apheresis market is projected to reach USD 3.9 billion by 2029 from USD 2.6 billion in 2024, at a CAGR 8.8 % from 2024 to 2029. Apheresis is the process of utilizing specialized medical equipment to extract specific components from the blood of a donor or patient, while simultaneously returning the remainder either with or without additional extracorporeal treatment. This process encompasses the use of devices and disposable materials employing centrifugation and membrane separation/filtration technologies for the precise isolation of blood components. The growth of this market is driven by increase in prevalence of the chronic diseases and upsurging number of trauma and injury cases.

The apheresis market is a highly consolidated market and is dominated by key players. The major players operating in apheresis market Terumo BCT, Inc. (Japan), Fresenius SE & Co. KGaA (Germany), Haemonetics Corporation (US), Baxter International Inc. (US), Asahi Kasei Medical Co., Ltd. (Japan), B. Braun Melsungen AG (Germany), Cerus Corporation (US), Kaneka Corporation (Japan), SB-Kawasumi Laboratories, Inc (Japan), Nikkiso Co., Ltd (Japan), Macopharma SA (France), Miltenyi Biotec (Germany), Otsuka Holdings Co., Ltd. (Japan), Medica S.p.A. (Italy), Mallinckrodt plc (Ireland), Becton, Dickinson and Company (US), LMB Technologie GmbH (Germany), Bioelettronica S.r.l. (Italy), Infomed SA (Switzerland), Cytosorbents Corporation (US), Medicap clinic GmbH (Germany), Haier Biomedical (China), Beijing ZKSK Technology Co., Ltd. (China), Guangzhou Daji Medical Science and Technology Co. Ltd (China), PuriBlood Medical (Taiwan).

To know about the assumptions considered for the study download the pdf brochure


Terumo BCT Inc., a subsidiary of Terumo Corporation, specializes in crafting healthcare solutions and products for the global market. In response to varying levels of access to safe blood and medical treatments worldwide, Terumo BCT concentrates on delivering therapeutic apheresis, blood components, and cellular technologies. The company's offerings encompass apheresis collections, manual and automated whole blood processing, and pathogen reduction, alongside therapeutic apheresis and cell-processing technologies. Terumo BCT distinguishes itself through a comprehensive suite of cutting-edge products, exemplified by its Spectra Optia System. Furthermore, the company serves a diverse clientele including hospitals, therapeutic apheresis centers, blood banks, biotech, and cell processing centers. A significant portion of the company's resources is dedicated to research and development, resulting in an expanded portfolio of innovative products. Moreover, Terumo BCT boasts a robust presence across various regions, with key markets in Asia, China, Japan, America, and EMEA. Through these strategic initiatives, Terumo aims to solidify its position as a leading player in the apheresis industry, positioning itself for sustained growth and success.


Fresenius SE & CO. KGaA, a leading global healthcare conglomerate, specializes in dialysis, hospital management, and outpatient medical services. The company is committed to project management and delivering comprehensive healthcare solutions to institutions worldwide. Its strategic focus includes penetrating emerging markets to bolster competitiveness. Apheresis products are marketed through its two key business divisions, Fresenius Kabi and Fresenius Medical Care, catering to both donor and therapeutic procedures. For its sustainable future growth and securing a competitive advantage in the dynamic healthcare sector the company emphasize research and development. Targeting various end users including hospitals, healthcare facilities, professionals, and dialysis service providers, Fresenius boasts a substantial presence across North America, Europe, Asia-Pacific, Latin America, and Africa, supported by robust distribution networks spanning all continents.


Haemonetics Corporation stands as a pivotal player in the apheresis market, renowned for its innovative solutions and comprehensive suite of apheresis equipment. As a leading global healthcare corporation, Haemonetics is dedicated to advancing patient care while optimizing healthcare cost efficiencies. Haemonetics provides advanced apheresis devices for both blood donation centers and hospitals, catering to various applications like plasmapheresis, plateletpheresis, and leukapheresis. Haemonetics' robust growth strategies encompass both organic and inorganic approaches, allowing the company to expand its market presence and capture new opportunities. This strategic approach ensures sustained relevance and competitiveness in the dynamic apheresis landscape. Moreover, company has significant operational footprint spanning major regions such as the US, Europe, Japan, and various parts of Asia, they have effectively penetrates key markets and serves a diverse clientele. Their products are marketed in approximately 90 countries worldwide, showcasing its global reach and market leadership.

Related Reports:

Apheresis Market by Product (Device (Centrifugation, Membrane Separation) Disposable), Procedure (Donor, Therapeutic), Application (Plasmapheresis, Plateletpheresis), Technology, End-User (Hospital, Blood Collection Center), Region - Global Forecast to 2029

Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]

Apheresis Market Size,  Share & Growth Report
Report Code
MD 1407
RI Published ON
Choose License Type

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
©2024 MarketsandMarkets Research Private Ltd. All rights reserved
DMCA.com Protection Status